No abstract

Вирусный гепатит С приобрел значение одной из глобальных проблем здравоохранения [1]. К клиническим особенностям гепатита С следует отнести высокую частоту хронизации процесса (85%). Прогрессирование хронического гепатита С (ХГС) в цирроз печени (20-30%) и гепатоцеллюлярную карциному (30-40%) приводит к инвалидизации, снижению продолжительности и качества жизни пациентов [2].

Goal. Paritrapeprir / ritonavir / ombitasvir / dasabuvir on the clinical and laboratory parameters, including thesubpopulation composition of lymphocytes, in patients with compensated cirrhosis in the outcome of chronic hepatitis C. Materials and methods. The study included patients with compensated liver cirrhosis class A (no more than 6 on the Child – Turcotte – Pugh scale), in the outcome of chronic hepatitis C, genotype 1b (group 1, n = 28). The comparison group (group 2, n = 25) consisted of patients comparable in terms of gender and main study parameters, not receiving antiviral therapy. Results. A stable virologic response was 96,8%. There were no serious adverse events requiring treatment reversal. As a result of treatment, there was a disappearance or a significant decrease in the severity of asthenovegetative and dyspeptic syndromes, a reduction in liver size, an improvement in liver functional parameters (biochemical response), and normalization of the balance of the cellular immunity by increasing CD3 +, CD4 +, CD8 + – CD16 + lymphocyte counts. The conclusion. Etiotropic therapy with paritrapeprir /ritonavir / ombitasvir / dasabuvir is well tolerated by patients with compensated cirrhosis in the outcome of chronic hepatitis C, has high efficacy, positively influences the dynamics of clinical manifestations, and also helps reduce the imbalance of the cellular immunity.

Background:Low back pain (LBP) and spine osteoarthritis are among the leading health-related causes of disability and reduction in patient quality of life. More recent work suggested that the factors that lead to disc degeneration may have important genetic components. Genetic predisposition has been confirmed by recent findings of associations between degeneration and gene polymorphisms of matrix macromolecules.Objectives:Evaluation of genetic polymorphisms of genes collagen 1A1 (COL1A1), interleikin 1β (IL-1β), interleikin 6 (IL-6), vitamin D receptor (VDR) in patients with LBP, associated with spine osteoarthritis.Methods:We examined 33 patients (men-17, women-16, middle age 28, 7±3,77) with LBP end onset, verified by magnetic resonance imaging (MRI) and 15 controls was carried out. Assessed the intensity of pain syndrome on visual analog scale (VAS, mm) and the nature of its current (IASP, 1994). Polymerase chain reaction and restriction fragments length polymorphism was used to detect the polymorphism of COL1A1 (rs 1800012), IL-1 (rs 1143627), IL-6 (rs 1800795), VDR (rs 1544410).Results:The severity of the pain (VAS) average was 60 mm, all the patients revealed chronic option currents pain syndrome. In 86 % of patients detected changes disc in the form of protrusions and hernias, 17 % of patients had a characteristic reducing the height of the intervertebral disc of lower height disc and osteophytes, arthritis facet joints identified in 20 % of patients in 34% of patients diagnosed changes type Modic II. In 83% of patients with LBP identified homozygous variant allele (GG) Col1A1 gene. The absence of T-alleles in the gene IL 1β in the group of patients was associated with severity of the disease. Carriage of allele in heterozygous AG found in 54% of patients of the main group and was not observed in the control that requires further accumulation of facts. Identified association GG-genotype of IL-6 clinical and instrumental signs of the syndrome Modic-II.Conclusion:These findings may be the reason for the patient-specific approach to diagnosing and treatment of back pain. It proves the necessity of research of genetic polymorphisms in patients with spine osteoarthritis.Disclosure of Interests: :None declared

No abstract